{
    "2021-04-07": [
        [
            {
                "time": "2021-04-01",
                "original_text": "Large-Cap Stocks to Buy and Hold to Start Q2",
                "features": {
                    "keywords": [
                        "Large-Cap",
                        "Buy",
                        "Hold",
                        "Q2"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "stocks"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-03-30",
                "original_text": "Pfizer’s Xeljanz Faces Canadian Review Amid More Scrutiny of JAK Inhibitors",
                "features": {
                    "keywords": [
                        "Pfizer",
                        "Xeljanz",
                        "Canadian Review",
                        "JAK Inhibitors",
                        "Scrutiny"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-03-29",
                "original_text": "Barron’s Stock Screen: The 5 ‘Dividend Aristocrats’ With the Fastest-Growing Payouts",
                "features": {
                    "keywords": [
                        "Dividend Aristocrats",
                        "Fastest-Growing",
                        "Payouts"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-28",
                "original_text": "AbbVie Submits Regulatory Applications for SKYRIZI® (risankizumab) in Psoriatic Arthritis to FDA and EMA",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "SKYRIZI",
                        "FDA",
                        "EMA",
                        "Regulatory Applications"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-27",
                "original_text": "AbbVie to Present Data Across its Robust Neuroscience Portfolio at the 2021 American Academy of Neurology (AAN) Annual Meeting",
                "features": {
                    "keywords": [
                        "AbbVie",
                        "Neuroscience",
                        "Data",
                        "AAN",
                        "Annual Meeting"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-03-26",
                "original_text": "Not All Dividend Aristocrats Are the Same. Here Are 5 With Fast-Growing Payouts",
                "features": {
                    "keywords": [
                        "Dividend Aristocrats",
                        "Fast-Growing",
                        "Payouts"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "dividends"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}